PULMICORT FLEXHALER Drug Patent Profile

✉ Email this page to a colleague

When do Pulmicort Flexhaler patents expire, and what generic alternatives are available?

Pulmicort Flexhaler is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in PULMICORT FLEXHALER is budesonide. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pulmicort Flexhaler

A generic version of PULMICORT FLEXHALER was approved as budesonide by TEVA PHARMS on November 18^th, 2008.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for PULMICORT FLEXHALER?
What are the global sales for PULMICORT FLEXHALER?
What is Average Wholesale Price for PULMICORT FLEXHALER?

Summary for PULMICORT FLEXHALER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PULMICORT FLEXHALER

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	PULMICORT FLEXHALER	budesonide	POWDER, METERED;INHALATION	021949-001	Jul 12, 2006		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Cheplapharm	PULMICORT FLEXHALER	budesonide	POWDER, METERED;INHALATION	021949-002	Jul 12, 2006		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for PULMICORT FLEXHALER

See the table below for patents covering PULMICORT FLEXHALER around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Japan	2001509811		⤷ Start Trial
Japan	S62221366	APPARATUS FOR POWDER DRUG INHALATOR	⤷ Start Trial
Slovakia	95999	NEW FORMULATION FOR INHALATION HAVING A POURED BULK DENSITY OF 0.28 TO 0.38 G/ML, A PROCESS FOR PREPARING THE FORMULATION AND THE USE THEREOF	⤷ Start Trial
European Patent Office	0975382		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for PULMICORT FLEXHALER

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	301102	Netherlands	⤷ Start Trial	PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	202140009	Slovenia	⤷ Start Trial	PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435024	LUC00208	Luxembourg	⤷ Start Trial	PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	132021000000095	Italy	⤷ Start Trial	PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

PULMICORT FLEXHALER: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Pulmicort Flexhaler (budesonide inhalation powder) is an inhaled corticosteroid primarily indicated for asthma management. As of 2023, it holds a significant position within the respiratory therapeutics segment, although its market is increasingly competitive due to the rise of biologics and alternative inhalation therapies. This report provides a detailed analysis of the current investment landscape, market dynamics, and projected financial trajectory for Pulmicort Flexhaler, supported by industry data, regulatory insights, and competitive analysis.

1. Overview of Pulmicort Flexhaler

Attribute	Details
Generic Name	Budesonide Inhalation Powder
Brand Name	Pulmicort Flexhaler
Therapeutic Class	Inhaled corticosteroid (ICS)
Indications	Asthma (paediatric and adult), COPD (off-label)
Approval Date (US)	2010 (FDA) - as a device, original formulation in 1992
Market Penetration	Dominant in pediatric asthma; significant in adult asthma

2. Market Size and Growth Dynamics

Global Market Overview (2022-2027 Projection)

Region	2022 Market Size (USD Billion)	CAGR (2022-2027)	Notes
North America	1.8	4.2%	Leading market, mature, high adoption rate
Europe	1.2	3.9%	Strong regulatory environment, high prevalence of asthma
Asia-Pacific	0.9	8.1%	Emerging market, rapid growth, expanding healthcare access
Latin America & MEA	0.3	5.3%	Growing awareness and diagnosis rates

Total Global Market (2022): USD 4.2 Billion
Projected (2027): USD 5.0 Billion

Drivers of Growth

Rising asthma prevalence globally (estimated at 339 million people in 2018, rising annually) (Global Initiative for Asthma, 2022)
Increased awareness and diagnosis, especially in emerging markets
Continued patent extensions and formulations improving patient adherence
Regulatory approvals for pediatric and adult indications

Constraints Impacting Growth

Patent expirations for key formulations (e.g., Pulmicort Nebulizer in some jurisdictions)
Competition from generic inhaled corticosteroids and combination inhalers
Market shift towards biologics for severe asthma (e.g., omalizumab, dupilumab)
Cost containment policies in healthcare systems (e.g., US Medicaid, European agencies)

3. Competitive Landscape

Major Players and Alternatives

Company	Product/Brand	Key Features	Market Share (approximate)
AstraZeneca	Pulmicort Flexhaler	Dry powder inhaler, pediatric/daily use	35-40%
GlaxoSmithKline	Flovent HFA	Metered-dose inhaler (MDI)	20-25%
Teva	Qvar RediHaler	Inhaled corticosteroid, licensed for asthma	10-15%
Others	Various generics	Lower-cost options	15-20%

Note: Exact market share varies regionally and is subject to patent status and formulary inclusion.

Patent & Regulatory Landscape

Patent Expiration: Likely to begin around 2025-2028 in significant markets, opening avenues for generics.
Regulatory Approvals: Approved in major markets including US, EU, Japan, and emerging countries.

4. Financial Trajectory and Investment Outlook

Revenue Trends

Year	Estimated Revenue (USD Billion)	YoY Growth	Commentary
2022	1.8	-	Stable, dominated by mature markets
2023	1.85	2.8%	Slight growth, efficacy of new formulations
2024	1.9	2.7%	Market saturation, generic competition looms
2025	2.0	5.3%	Potential patent expiry, off-patent strategies
2026	2.1	5.0%	Entry of generics, growth from emerging markets
2027	2.3	9.5%	Market penetration, new formulations/indications

Profitability and Investment Considerations

Factor	Impact	Details
Patent Status	High	Revenue stability pre-expiry; decline post-expiry unless differentiation or pipeline expansion
R&D Pipeline	Moderate	Development of combination therapies, novel formulations, and delivery systems
Cost of Goods	Moderate	Manufacturing efficiencies are critical in competing with generics
Market Expansion	High	Targeting pediatric and emerging markets accelerates growth

Potential Investment Strategies

Strategy	Rationale	Risks
Hold / Maintain	Leverage existing brand dominance, focus on incremental innovations	Patent expiration, generic entry
Partner / License	Collaborate on combination therapies or new inhalation devices	Dependence on third-party innovation
Invest in Pipeline	Focus on biologics or advanced delivery systems	R&D risks, regulatory hurdles
Divest / Reduce Exposure	Anticipate market erosion post-patent	Loss of established revenue streams

5. Market Dynamics: Drivers, Barriers, and Trends

Key Market Drivers

Epidemiology: Rising asthma prevalence, especially in Asia-Pacific
Healthcare Infrastructure: Improved access and diagnostic capabilities
Technological Advancements: Development of dry powder inhalers enhancing adherence
Policy Initiatives: Focus on respiratory health by governments and WHO

Market Barriers

Patent cliffs leading to price competition
The high cost of inhalation therapy devices
Healthcare policy constraints favoring generics
Competitive emergence of biologics for severe cases

Emerging Trends

Shift towards personalized inhalation therapies
Integration of digital health solutions for adherence
Development of combination inhalers (ICS + LABA)
Focus on pediatric formulations with easier delivery mechanisms

6. Comparative Analysis with Competitors

Parameter	Pulmicort Flexhaler	Flovent HFA (GSK)	Qvar RediHaler (Teva)	Biologic Alternatives
Formulation	Dry powder inhaler	Metered-dose inhaler	Breath-actuated inhaler	Injectable biologics
Market Share (Global, 2022)	Approx. 35-40%	20-25%	10-15%	Niche, high-cost segment
Patent Status	Expiring 2025-2028	Similar	Similar	Patents extended via biologic innovations
Pricing (USD)	Moderate	Moderate	Moderate	High (USD 10K+/dose)
Preferred Patient Demographics	Pediatric, moderate asthma	Adult asthma	Pediatric and adult	Severe asthma, eosinophilic

7. Regulatory and Policy Impact

Region	Key Regulations	Implication for Pulmicort Flexhaler
US	FDA regulations, patent cliffs	Patent expiration expected 2025-2028, need for biosimilar pathways
EU	EMA policies, drug pricing regulations	Price negotiations can pressure margins
Asia-Pacific	Regulatory divergence, accelerating approvals	Opportunities with local manufacturing and registration
International	WHO guidelines promoting inhaler therapy	Foster expansion in low-income regions

8. Summary and Future Outlook

Current Position: Pulmicort Flexhaler remains a leading inhaled corticosteroid for asthma, with stable revenue in mature markets. Its dominant market share hinges on pediatric usage and established clinical safety profiles.

Market Risks: Patent expirations threaten revenue; competition from generics and biologics accelerates market erosion. Cost containment policies may further compress margins.

Growth Opportunities: Expansion into emerging markets, development of combination inhalers, and innovation in inhalation device technology can extend the product lifecycle.

Investment Recommendations: Maintain exposure with strategic vigilance on patent expiries; explore opportunities in pipeline development and potential biosimilars. Diversification into biologics for severe asthma represents a strategic hedge.

Key Takeaways

Insight	Implication for Investors and Stakeholders
Market Saturation with Growth Potential in Emerging Regions	Prioritize investments in Asia-Pacific and Latin America; local partnerships can accelerate growth.
Patent Expirations Around 2025-2028	Prepare for generic competition; consider biosimilar development or pipeline diversification.
Technological Advancements Enhance Patient Adherence	Engage in innovation targeting inhaler design and digital health integration.
Competitive Landscape Favoring Price and Formulation Innovation	Invest in R&D for next-generation inhalers or combination therapies to sustain market share.
Regulatory Environment is Critical for Market Access	Monitor regional policies for timely approval and reimbursement strategies.

FAQs

Q1. When is Pulmicort Flexhaler expected to lose patent protection, and what does this mean for investors?
The primary patent is anticipated to expire between 2025 and 2028. This will likely open the market to generic entrants, exerting downward pressure on prices and margins, necessitating strategic planning for patent cliff management.

Q2. How is the rise of biologics affecting Pulmicort's market segment?
Biologics target severe asthma, representing a growing niche but not directly replacing inhaled corticosteroids like Pulmicort, which are first-line therapy. However, competition in broader respiratory therapeutics could influence overall market share.

Q3. What regions offer the highest growth opportunities for Pulmicort Flexhaler?
Asia-Pacific and Latin America present the strongest growth prospects due to rising asthma prevalence and expanding healthcare infrastructure.

Q4. What innovations could prolong the commercial viability of Pulmicort Flexhaler?
Development of combination inhalers incorporating LABAs, improved delivery devices, and digital adherence tools are key innovations.

Q5. What pricing strategies should companies adopt amid increasing generic competition?
Competitive pricing, formulary positioning, and demonstrating clinical superiority or convenience can sustain market share during patent expiries.

References

Global Initiative for Asthma (GINA). "Global Strategy for Asthma Management and Prevention," 2022.
IQVIA, "Global Respiratory Inhalers Market Report," 2022.
FDA, "Pulmicort (budesonide) Inhalation Powder," 2010.
AstraZeneca, "Pulmicort Flexhaler Product Information," 2023.
European Medicines Agency (EMA), "Respiratory Inhalers Market Overview," 2022.

More… ↓

⤷ Start Trial